维奈克拉联合硼替佐米和地塞米松治疗复发/难治性多发性骨髓瘤疗效 promising 且安全性可接受
这项1b期试验纳入66例复发/难治性多发性骨髓瘤患者,接受每日维奈克拉(50-1200 mg,安全性扩展组800 mg)联合硼替佐米和地塞米松。总缓解率为67%(44/66),42%达到非常好的部分缓解或更好;中位至进展时间和缓解持续时间分别为9.5和9.7个月。该联合方案安全性可接受且疗效 promising。
要点
- 维奈克拉联合硼替佐米和地塞米松在复发/难治性多发性骨髓瘤中总缓解率为67%。
- 42%的患者达到非常好的部分缓解或更好。
- 常见不良事件包括轻度胃肠道毒性和3/4级血细胞减少。
核心结论
- 维奈克拉联合硼替佐米和地塞米松在复发/难治性多发性骨髓瘤患者中具有可接受的安全性特征和 promising 的疗效。
研究设计与样本
- 1b期试验,纳入66例复发/难治性多发性骨髓瘤患者(剂量递增队列54例,安全性扩展队列12例)。
- 患者接受每日维奈克拉(50-1200 mg,按指定剂量队列;安全性扩展组800 mg)联合硼替佐米和地塞米松。
- 患者既往接受过中位3线治疗(范围1-13);26例(39%)对既往硼替佐米难治,35例(53%)对来那度胺难治;39例(59%)既往接受过干细胞移植。
主要发现
- 总缓解率为67%(44/66);42%达到非常好的部分缓解或更好(≥VGPR)。
- 中位至进展时间和缓解持续时间分别为9.5个月和9.7个月。
- 对硼替佐米不耐药且既往接受1至3线治疗的患者中,总缓解率为97%,≥VGPR为73%。
- BCL2高表达患者的总缓解率(94% [17/18])高于BCL2低表达患者(59% [16/27])。
- 常见不良事件包括轻度胃肠道毒性(腹泻[46%]、便秘[41%]和恶心[38%])和3/4级血细胞减少(血小板减少[29%]和贫血[15%])。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The antiapoptotic proteins BCL-2 and myeloid cell leukemia sequence 1 (MCL-1) promote multiple myeloma (MM) cell survival. Venetoclax is a selective, orally bioavailable small-molecule BCL-2 inhibitor; bortezomib can indirectly inhibit MCL-1. In preclinical studies, venetoclax enhanced bortezomib activity, suggesting that cotargeting of BCL-2 and MCL-1 could be an effective treatment strategy in myeloma. This phase 1b trial studied patients with relapsed/refractory MM receiving daily venetoclax (50-1200 mg per designated dose cohort; 800 mg in safety expansion) in combination with bortezomib and dexamethasone. A total of 66 patients were enrolled (54 in the dose-escalation cohorts and 12 in the safety expansion). Patients had received a median of 3 prior therapies (range, 1-13); 26 (39%) were refractory to prior bortezomib and 35 (53%) to lenalidomide; 39 (59%) had prior stem cell transplant. The combination was generally well tolerated, and common adverse events included mild gastrointestinal toxicities (diarrhea [46%], constipation [41%], and nausea [38%]) and grade 3/4 cytopenias (thrombocytopenia [29%] and anemia [15%]). The overall response rate (ORR) was 67% (44/66); 42% achieved very good partial response or better (≥VGPR). Median time to progression and duration of response were 9.5 and 9.7 months, respectively. ORR of 97% and ≥VGPR 73% were seen in patients not refractory to bortezomib who had 1 to 3 prior therapies. Patients with high BCL2 expression had a higher ORR (94% [17/18]) than patients with low BCL2 expression (59% [16/27]). This novel combination of venetoclax with bortezomib and dexamethasone has an acceptable safety profile and promising efficacy in patients with relapsed/refractory MM. This trial was registered at www.clinicaltrials.gov as #NCT01794507.
引用
- Moreau P, Chanan-Khan A, Roberts AW, et al. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. Blood. 2017. PMID: 28847998. doi:10.1182/blood-2017-06-788323
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。